Oncolinx is developing the next generation of antibody-drug conjugates (ADCs)--powerful, targeted cancer therapies that have dramatically fewer side effects. These therapies can be targeted to nearly any type of cancer, and are rapidly becoming the state-of-the-art in cancer treatment. Drawing on the scientific innovation of the National Cancer Institute, the world's leading biotechs and life sciences companies, Oncolinx is redefining the paradigm of cancer therapy.

2014 Boston Silver Winner